Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02493751 · ClinicalTrials.gov registry record · Phase 1
A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT02493751 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 55 participants.
The verdict
NCT02493751, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
This is a Phase 1b, open-label, multi-center, multiple-dose trial designed to estimate the maximum tolerated dose (MTD) and select the recommended phase 2 dose (RP2D) of avelumab (MSB0010718C) in combination with axitinib (AG-013736). Once the MTD of avelumab administered in combination with axitinib is estimated (dose finding portion), the dose expansion phase will be opened to further characterize the combination in term of safety profile, anti tumor activity, pharmacokinetics, pharmacodynamics and biomarker modulation.
Interventions
- DRUG Axitinib (AG-013736)
- DRUG Avelumab (MSB0010718C)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2015-10-26 |
| Est. Completion | 2021-03-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02493751
The ClinicalTrials.gov registry entry for NCT02493751 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Axitinib (AG-013736) is the first listed.
NCT02493751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02493751 about?
NCT02493751 is a clinical study titled "A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)". This is a Phase 1b, open-label, multi-center, multiple-dose trial designed to estimate the maximum tolerated dose (MTD) and select the recommended phase 2 dose (RP2D) of avelumab (MSB0010718C) in combination with axitinib (AG-013736). Once the MTD of avelumab administered in combination with axitini...
What is the current status of trial NCT02493751?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2015-10-26. Estimated completion is 2021-03-04.
What interventions are being tested in trial NCT02493751?
The interventions under investigation include: Axitinib (AG-013736) (DRUG), Avelumab (MSB0010718C) (DRUG).
Who is sponsoring clinical trial NCT02493751?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.